New pill aims to tame tough blood pressure in kidney patients

NCT ID NCT03574363

Completed Disease control Sponsor: KBP Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called KBP-5074 in 162 people with moderate-to-severe chronic kidney disease whose blood pressure was still high despite treatment. Participants took either a low or high dose of the drug or a placebo daily for 84 days. The main goal was to see if the drug could lower blood pressure more than a placebo, and researchers also checked its safety and how the body processes it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KBP-5074 (a mineralocorticoid receptor antagonist) tablet
What this could lead to: If successful, this could lead to a new treatment option to better control blood pressure and possibly slow kidney disease progression in patients with advanced chronic kidney disease.
What could go wrong: This is an early Phase 2 trial with only 162 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects like high potassium or kidney function changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES HYPERTENSION

Contacts and locations

Locations

KBP Biosciences USA Inc

Princeton, New Jersey, 08540, United States
Worldwide Clinical Trials

Morrisville, North Carolina, 27560, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.